Repligen Stock Price, News & Analysis (NASDAQ:RGEN)

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RGEN shares.
View RGEN analyst ratings or view top-rated stocks.

11 equities research analysts have issued 1 year target prices for Repligen's shares. Their RGEN share price targets range from $165.00 to $210.00. On average, they anticipate the company's stock price to reach $189.55 in the next year. This suggests a possible upside of 19.0% from the stock's current price.
View analysts price targets for RGEN or view top-rated stocks among Wall Street analysts.

Repligen's stock was trading at $169.31 at the start of the year. Since then, RGEN stock has decreased by 5.9% and is now trading at $159.27.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our RGEN earnings forecast.

Repligen Co. (NASDAQ:RGEN) announced its quarterly earnings data on Tuesday, October, 31st. The biotechnology company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.14 by $0.09. The biotechnology company earned $141.20 million during the quarter, compared to analysts' expectations of $140.68 million. Repligen had a net margin of 17.29% and a trailing twelve-month return on equity of 6.08%. Repligen's revenue for the quarter was down 29.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.77 earnings per share.

ETFs with the largest weight of Repligen (NASDAQ:RGEN) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Invesco Biotechnology & Genome ETF (PBE), BlackRock Future Innovators ETF (BFTR), Fidelity Disruptive Medicine ETF (FMED), VanEck Biotech ETF (BBH), Nuveen ESG Mid-Cap Growth ETF (NUMG), BNY Mellon Innovators ETF (BKIV) and Invesco ESG NASDAQ Next Gen 100 ETF (QQJG).

Repligen issued an update on its FY23 earnings guidance on Tuesday, October, 31st. The company provided EPS guidance of $1.70-1.76 for the period, compared to the consensus earnings per share estimate of $1.74. The company issued revenue guidance of $635-645 million, compared to the consensus revenue estimate of $644.49 million.

13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

Repligen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Sands Capital Management LLC (2.81%), Artisan Partners Limited Partnership (2.79%), Wellington Management Group LLP (2.50%), Bank of New York Mellon Corp (2.14%), Ameriprise Financial Inc. (2.07%) and Impax Asset Management Group plc (1.74%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, Jon Snodgres, Karen A Dawes, Karen A Dawes, Manner Carrie Eglinton, Martin D Madaus, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends.

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.